StockData
Organon & Co. logo

Organon & Co. (OGN) stock

OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/3013% above fair value
$13.92+0.02 (+0.14%)

Close on Nov 18, 2026Market cap $3.66BP/E 18.1Yield 2.44%

Earnings

Organon's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2026
$1.46B
-3.5% on a year earlier
non-GAAP Adjusted diluted earnings per share, Q1 FY2026
$0.71
$1.02 a year earlier
Latest guidance
Lowered
Feb 12, 2026 · 8 items

Quarterly results

Revenue and earnings per share from each of Organon's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q1 FY2026ended Mar 31, 2026Apr 30, 2026before the open$1.46B-3.5%$0.55$0.71Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026before the open$1.51B-5.3%-$0.79$0.63Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open$1.60B+1.3%$0.61$1.01Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$1.59B-0.8%$0.56$1.00Release
Q1 FY2025ended Mar 31, 2025May 1, 2025before the open$1.51B-6.7%$0.33$1.02Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025before the open$1.59B-0.4%$0.42$0.90Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024before the open$1.58B+4.1%$1.38$0.87Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$1.61B-0.1%$0.75$1.12Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open$1.62B+5.5%$0.78$1.22Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024before the open$1.60B+7.6%$2.13$0.88Release
Q3 FY2023ended Sep 30, 2023Nov 2, 2023before the open$1.52B-1.2%$0.23$0.87Release
Q2 FY2023ended Jun 30, 2023Aug 8, 2023before the open$1.61B+1.5%$0.95$1.31Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Organon's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$6.20B–NewFeb 12, 2026
Adjusted EBITDAnon-GAAPFY2026$1.90B–NewFeb 12, 2026
Depreciationnon-GAAPFY2026$140.00M–LoweredFeb 12, 2026
Effective non-GAAP tax ratenon-GAAPFY202627.5% – 29.5%–NewFeb 12, 2026
Ex-FX revenue growthnon-GAAPFY2026-1.5%–NewFeb 12, 2026
Fully diluted weighted average shares outstandingnon-GAAPFY2026265–NewFeb 12, 2026
FX translation impactnon-GAAPFY2026$75.00M–LoweredFeb 12, 2026
Interestnon-GAAPFY2026$500.00M–NewFeb 12, 2026

Guidance vs results

The last range Organon gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$6.20B – $6.25B$6.22BΣ4QWithin range
FY2025Revenue growth-3.2% – -2.4%-2.92%Σ4QWithin range

Guidance history

Every forecast Organon put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Feb 12, 2026Adjusted EBITDAFY2026$1.90BNew
Feb 12, 2026Effective non-GAAP tax rateFY202627.5% – 29.5%New
Feb 12, 2026Fully diluted weighted average shares outstandingFY2026265New
Feb 12, 2026InterestFY2026$500.00MNew
Feb 12, 2026DepreciationFY2026$140.00MLowered
Feb 12, 2026FX translation impactFY2026$75.00MLowered
Feb 12, 2026Ex-FX revenue growthFY2026-1.5%New
Feb 12, 2026revenueFY2026$6.20BNew
Nov 10, 2025Adjusted gross marginFY202560% – 61%Reaffirmed
Nov 10, 2025Adjusted EBITDA margin (Non-GAAP)FY202531%New
Nov 10, 2025Fully diluted weighted average shares outstandingFY2025263Reaffirmed
Nov 10, 2025Effective non-GAAP tax rateFY202522.5% – 24.5%Reaffirmed
Nov 10, 2025InterestFY2025$510.00MRaised
Nov 10, 2025DepreciationFY2025$135.00MLowered
Nov 10, 2025IPR&D*FY2025$6.00MLowered
Nov 10, 2025Ex-FX revenue growthFY2025-3.7% – -3.1%Lowered
Nov 10, 2025Nominal revenue growthFY2025-3.2% – -2.4%New
Nov 10, 2025RevenueFY2025$6.20B – $6.25BLowered
Aug 5, 2025Adjusted gross marginFY202560% – 61%New
Aug 5, 2025Fully diluted weighted average shares outstandingFY2025263New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Organon filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Results
  4. Update
  5. Results
  6. Results
  7. Results
  8. Results
  9. News
  10. Results
  11. Results
  12. News
  13. Results
  14. Results
  15. Update

See a number that looks wrong?